Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
Authors:
- Joyce O'SHaughnessyJOJoyce O'SHaughnessy
- Svetislava J. VukeljaSVSvetislava J. Vukelja
- Thomas MarslandTMThomas Marsland
- Gary KimmelGKGary Kimmel
- Suresh RatnamSRSuresh Ratnam
- John PippenJPJohn Pippen
- 1 May 2002
- journal article
- clinical trial
- Published by Elsevier in Clinical Breast Cancer
- Vol. 3, S17-S20
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Gemcitabine as First-Line Therapy in Patients with Metastatic Breast Cancer: A Phase II TrialOncology, 2002
- Single-Agent Gemcitabine Is Active in Previously Treated Metastatic Breast CancerOncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- First-line, single-agent Herceptin® (trastuzumab) in metastatic breast cancerEuropean Journal of Cancer, 2001
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerThe Breast, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancerAnti-Cancer Drugs, 1999
- Advanced breast cancer: a phase II trial with gemcitabine.Journal of Clinical Oncology, 1995
- 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia CellsNucleosides, Nucleotides & Nucleic Acids, 1989